心不全の薬物治療
Patrick Rossignol1, Adrian F Hernandez2, Scott D Solomon3
1Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, Institut National de la Santé et de la Recherche Médicale (Inserm), Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Inserm U1116, and French Clinical Research Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (FCRIN INI-CRCT), Nancy, France.
Lancet (London, England)
|March 13, 2019
まとめ
心不全の治療は慢性的なエジェクション分数の減少では著しく進歩したが,急性解消または保存されたエジェクション分数の治療ではそうではなかった. 患者さんの治療成果を向上させるには 根拠に基づいた薬物療法や 疾病管理プログラムの最適化が不可欠です
科学分野:
- 心臓病科
- 薬理学について
- 内科 医学
背景:
- 心不全は60歳以上の人の入院の主な原因です.
- 慢性心不全の治療において,エジェクション分数が減少した治療において,著しい進歩が見られた.
- 急性不補償性心不全およびエジェクション分子が保存された心不全に対する生存改善の有効な治療法は依然として限られている.
研究 の 目的:
- 心不全の現在の薬物治療の簡潔な要約を提供するためです.
- 国際的な心不全ガイドラインの実施を支援する.
- 専門家の経験に基づいた証拠不足の分野への洞察を提供すること.
主な方法:
- 心不全に対する利用可能な薬物治療のレビュー
- レニン・アニオテンシン・アルドステロン系阻害剤とベータブロッカーを含む,証拠に基づいた治療法を強調する.
- 実施課題と疾病管理プログラムの役割についての議論
主要な成果:
- 証拠に基づいた薬物治療の最適な実施は不可欠です.
- 現在の心不全治療の 実践的な応用には 課題があります
- 疾病管理プログラムでは 介護の最適化に多学科的なアプローチが提供されます
結論:
- 証拠に基づいた薬物治療に 継続的に焦点を当てることが不可欠です
- 実施の障壁を克服することは 心不全の管理を改善するための鍵です
- 多分野疾患管理プログラムは 患者のケアと成果を向上させることができます
関連する概念動画
01:22Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
01:26Heart Failure Drugs: Inotropic Agents
1.4K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.4K
01:22Heart Failure Drugs: β-Blockers
886
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
886
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K
01:17Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
01:27Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829